Actively Recruiting
Study to Evaluate Safety and Effects of ANXV Recombinant Human Annexin A5 Protein in Adults With Diabetic Retinopathy or Recent Retinal Vein Occlusion
Led by Annexin Pharmaceuticals AB · Updated on 2025-12-02
12
Participants Needed
1
Research Sites
N/A
Total Duration
AI-Summary
What This Trial Is About
Researchers are evaluating the safety and how the investigational medicine ANXV works in adults with non-proliferative diabetic retinopathy NPDR or recent onset retinal vein occlusion RVO. The study aims to find out if ANXV is safe, if it improves vision or vision-related findings caused by these eye conditions, and if it reduces the need for rescue medication. Different dose levels of ANXV will be compared to determine an appropriate dose for future studies. Participants will receive ANXV through a 30-minute intravenous infusion once daily for five days. The study includes 11 visits over a four-month period one screening visit, five treatment visits, and five follow-up visits. Dose levels being tested include 1 mg, 4 mg, and 6 mg. Safety will be monitored closely, and if concerns arise in either NPDR or RVO groups, lower doses may be started independently for each group. During the study, participants will undergo various eye assessments such as visual acuity tests, retinal imaging, electroretinography, and eye pressure measurements. Non-eye tests include vital signs, ECG, blood and urine safety labs, and study-specific blood tests. Researchers will track safety and tolerability from day 1 to day 120, measure ANXV levels during treatment, and monitor the use of rescue medications. Participants will visit the clinic regularly for checkups and tests, with the total study duration lasting about four months.
CONDITIONS
Brief Title
Safety and Proof of Concept Study of ANXV (Annexin A5) in Patients With Diabetic Retinopathy or Retinal Vein Occlusion
Research Team
A
Anna Frostegård
S
Susan Suchdev
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here